BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) Financials
Newest figures come from the 10-Q for Q3 FY2026, filed Jun 9, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BCTXL SEC filings page.
This page shows BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
BriaCell Therapeutics Corp. Warrant expiring 2031 does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
BriaCell Therapeutics Corp. Warrant expiring 2031 passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, all 2 leverage/liquidity signals pass.
BriaCell Therapeutics Corp. Warrant expiring 2031 reported a net loss of $26.3M while operations used $28.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
BriaCell Therapeutics Corp. Warrant expiring 2031 reported an operating loss of $27.2M against $37K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
BriaCell Therapeutics Corp. Warrant expiring 2031's EBITDA was -$7.6M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 20.4% from the same quarter a year earlier. Against the prior quarter it is down 1.1%.
BriaCell Therapeutics Corp. Warrant expiring 2031 reported -$7.2M in net income in Q3 2026. This represents a decrease of 16.9% from the same quarter a year earlier. Against the prior quarter it is up 0.8%.
BriaCell Therapeutics Corp. Warrant expiring 2031 earned -$0.99 per diluted share (EPS) in Q3 2026.
Not reported for Q3 2026.
Cash & Balance Sheet
BriaCell Therapeutics Corp. Warrant expiring 2031 held $6.9M in cash as of Q3 2026; long-term debt is not reported for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
BriaCell Therapeutics Corp. Warrant expiring 2031's ROE was -30.6% in Q3 2026, measuring profit generated per dollar of shareholder equity. This is up 20.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 6.7 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
BriaCell Therapeutics Corp. Warrant expiring 2031 invested $6.0M in research and development in Q3 2026. This represents an increase of 24.0% from the same quarter a year earlier. Against the prior quarter it is down 1.4%.
Not reported for Q3 2026.
Not reported for Q3 2026.
BCTXL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $6.0M+24.0% | $6.1M+6.5% | $6.7M+82.3% | N/A | $4.8M-37.2% | $5.7M-31.2% | $3.7M-46.5% | N/A |
| SG&A Expenses | $1.7M+9.0% | $1.5M-0.5% | $1.6M+10.2% | N/A | $1.5M-3.4% | $1.5M-5.6% | $1.5M-9.6% | N/A |
| Operating Income | -$7.6M-20.4% | -$7.5M-5.0% | -$8.3M-61.5% | N/A | -$6.3M+31.4% | -$7.2M+27.1% | -$5.2M+39.4% | N/A |
| EBITDA | -$7.6M-20.4% | -$7.5M-5.1% | -$8.3M-61.8% | N/A | -$6.3M+31.7% | -$7.1M+27.3% | -$5.1M+39.6% | N/A |
| Interest Expense | $30K-19.9% | N/A | N/A | N/A | $37K | N/A | N/A | N/A |
| Net Income | -$7.2M-16.9% | -$7.2M-14.8% | -$8.2M-41.3% | N/A | -$6.1M-457.1% | -$6.3M+44.3% | -$5.8M-196.7% | N/A |
| EPS (Basic) | -$0.99+94.0% | -$2.58+88.9% | -$4.35+86.7% | -$55.49-37.6% | -$16.42-1119.9% | -$23.31-119.1% | -$32.67-8697.4% | -$40.32-26780.0% |
| EPS (Diluted) | -$0.99 | -$2.58 | -$4.35 | -$55.49 | -$16.42 | -$23.31 | -$32.67 | -$40.32 |
| Diluted Shares (Avg) | 7M | 3M | 2M | N/A | 373,067 | 269,957 | 177,606 | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
BCTXL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $27.1M+59.2% | $33.6M+258.8% | $13.1M+25.5% | $21.6M+268.7% | $17.0M+174.1% | $9.4M-23.4% | $10.4M-44.1% | $5.9M-78.4% |
| Current Assets | $25.4M+71.7% | $32.2M+349.3% | $11.3M+38.1% | $19.9M+445.4% | $14.8M+167.4% | $7.2M-39.0% | $8.2M-55.4% | $3.7M-86.4% |
| Cash & Equivalents | $6.9M-44.8% | $29.9M+496.4% | $2.7M-53.1% | $10.5M+1117.3% | $12.5M+1231.7% | $5.0M-19.7% | $5.8M-57.6% | $862K-95.9% |
| Short-Term Investments | $15.9M | $0 | $7.5M | $7.4M | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $3.7M-27.6% | $3.4M-44.9% | $3.7M-44.4% | $4.3M-49.6% | $5.1M-59.3% | $6.1M-70.1% | $6.7M-58.4% | $8.6M-72.3% |
| Current Liabilities | $3.6M-17.1% | $3.2M-39.1% | $3.3M-33.5% | $4.0M-46.7% | $4.3M-35.9% | $5.2M+33.3% | $5.0M+376.7% | $7.5M+314.2% |
| Non-Current Liabilities | $72K-90.2% | $195K-78.5% | $407K-76.2% | $338K-69.2% | $730K-87.1% | $906K-94.6% | $1.7M-88.6% | $1.1M-96.2% |
| Total Equity | $23.4M+96.0% | $30.2M+836.3% | $9.4M+151.8% | $17.3M+745.6% | $11.9M+291.6% | $3.2M+138.8% | $3.7M+47.6% | -$2.7M+28.9% |
| Retained Earnings | -$134.3M-29.6% | -$127.2M-30.4% | -$120.0M-31.5% | -$111.8M-30.8% | -$103.7M-23.1% | -$97.5M-13.5% | -$91.2M-22.2% | -$85.4M-5.9% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
BCTXL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.0M+2.0% | -$8.0M-34.6% | -$7.7M-10.8% | -$8.1M-101.5% | -$7.2M-40.9% | -$5.9M+20.0% | -$7.0M+8.5% | -$4.0M+63.0% |
| Depreciation & Amortization | $29K+27.8% | $23K0.0% | $23K0.0% | $23K | $23K+498.5% | $23K+498.0% | $23K+498.2% | N/A |
| Stock-Based Compensation | N/A | $286K+0.3% | $295K+10.4% | N/A | $225K-42.7% | $285K-43.0% | $267K-50.0% | N/A |
| Investing Cash Flow | -$16.0M-15141.0% | $7.3M+9810.0% | -$75K0.0% | -$7.4M-1518.0% | -$105K | -$75K | -$75K | -$457K |
| Financing Cash Flow | $0-100.0% | N/A | N/A | $13.6M | $14.7M | $5.2M | $12.0M | N/A |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
BCTXL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -30.6%+20.7pp | -23.9%+171.1pp | -87.7%+68.6pp | N/A | -51.3% | -195.0% | -156.3%-394.8pp | N/A |
| Return on Assets | -26.5%+9.6pp | -21.5%+45.7pp | -62.7%-7.0pp | N/A | -36.0%-63.7pp | -67.2%+25.1pp | -55.7%-87.9pp | N/A |
| Current Ratio | 7.07+3.7x | 10.10+8.7x | 3.42+1.8x | 5.01+4.5x | 3.41+2.6x | 1.37-1.6x | 1.65-15.9x | 0.49-14.5x |
| Debt-to-Equity | 0.16-0.3x | 0.11-1.8x | 0.40-1.4x | 0.25 | 0.42 | 1.90 | 1.80-4.6x | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Where BriaCell Therapeutics Corp. Warrant expiring 2031 Ranks
Frequently Asked Questions
Is BriaCell Therapeutics Corp. Warrant expiring 2031 profitable?
No, BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) reported a net income of -$26.3M in fiscal year 2025.
What is BriaCell Therapeutics Corp. Warrant expiring 2031's EBITDA?
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) had EBITDA of -$27.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is BriaCell Therapeutics Corp. Warrant expiring 2031's return on equity (ROE)?
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) has a return on equity of -151.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is BriaCell Therapeutics Corp. Warrant expiring 2031's operating cash flow?
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) recorded an outflow of $28.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are BriaCell Therapeutics Corp. Warrant expiring 2031's total assets?
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) had $21.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does BriaCell Therapeutics Corp. Warrant expiring 2031 spend on research and development?
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) invested $21.3M in research and development during fiscal year 2025.
What is BriaCell Therapeutics Corp. Warrant expiring 2031's current ratio?
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) had a current ratio of 5.01 as of fiscal year 2025, which is generally considered healthy.
What is BriaCell Therapeutics Corp. Warrant expiring 2031's debt-to-equity ratio?
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is BriaCell Therapeutics Corp. Warrant expiring 2031's return on assets (ROA)?
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) had a return on assets of -121.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does BriaCell Therapeutics Corp. Warrant expiring 2031's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) held $17.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $28.2M over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is BriaCell Therapeutics Corp. Warrant expiring 2031's Piotroski F-Score?
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BriaCell Therapeutics Corp. Warrant expiring 2031's earnings high quality?
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) reported a net loss of $26.3M while operations used $28.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can BriaCell Therapeutics Corp. Warrant expiring 2031 cover its interest payments?
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) reported an operating loss of $27.2M against $37K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.